The Committee for Medicinal Products for Human Use (CHMP), formerly known as Committee for Proprietary Medicinal Products (CPMP), is the European Medicines Agency

European Medicines Agency

The European Medicines Agency is a European agency for the evaluation of medicinal products. From 1995 to 2004, the European Medicines Agency was known as European Agency for the Evaluation of Medicinal Products.Roughly parallel to the U.S...

's committee

Committee

A committee is a type of small deliberative assembly that is usually intended to remain subordinate to another, larger deliberative assembly—which when organized so that action on committee requires a vote by all its entitled members, is called the "Committee of the Whole"...

responsible for elaborating the agency's opinions on all issues regarding medicinal products for human use.

E.g.: In June 2007 the CHMP has recommended restrictions on the use of piroxicam because of the increased risk of gastro-intestinal side effects and serious skin reactions. The CHMP has advised that:

• piroxicam should be initiated only by physicians experienced in treating inflammatory or degenerative rheumatic diseases
• piroxicam should not be used as first-line treatment
• in adults, use of piroxicam should be limited to the symptomatic relief of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis
• piroxicam dose should not exceed 20 mg daily
• piroxicam should no longer be used for the treatment of acute painful and inflammatory conditions
• treatment should be reviewed 2 weeks after initiating piroxicam, and periodically thereafter
• concomitant administration of a gastro-protective agent (section 1.3) should be considered
• Topical preparations containing piroxicam are not affected by these restrictions

External links

• European Medicines Agency - Committee for Medicinal Products for Human Use (CHMP)